BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16075413)

  • 1. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
    Woolford LB; Southgate TD; Margison GP; Milsom MD; Fairbairn LJ
    J Gene Med; 2006 Jan; 8(1):29-34. PubMed ID: 16075413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
    Clemons M; Kelly J; Watson AJ; Howell A; McElhinney RS; McMurry TB; Margison GP
    Br J Cancer; 2005 Nov; 93(10):1152-6. PubMed ID: 16278661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
    Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
    Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
    Fontes AM; Davis BM; Encell LP; Lingas K; Covas DT; Zago MA; Loeb LA; Pegg AE; Gerson SL
    Mol Cancer Ther; 2006 Jan; 5(1):121-8. PubMed ID: 16432170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
    Kreklau EL; Pollok KE; Bailey BJ; Liu N; Hartwell JR; Williams DA; Erickson LC
    Mol Cancer Ther; 2003 Dec; 2(12):1321-9. PubMed ID: 14707273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K).
    Maier P; Spier I; Laufs S; Veldwijk MR; Fruehauf S; Wenz F; Zeller WJ
    Gene Ther; 2010 Mar; 17(3):389-99. PubMed ID: 19865182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro.
    Turriziani M; Caporaso P; Bonmassar L; Buccisano F; Amadori S; Venditti A; Cantonetti M; D'Atri S; Bonmassar E
    Pharmacol Res; 2006 Apr; 53(4):317-23. PubMed ID: 16412662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
    Davis BM; Roth JC; Liu L; Xu-Welliver M; Pegg AE; Gerson SL
    Hum Gene Ther; 1999 Nov; 10(17):2769-78. PubMed ID: 10584923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
    Barvaux VA; Lorigan P; Ranson M; Gillum AM; McElhinney RS; McMurry TB; Margison GP
    Mol Cancer Ther; 2004 Oct; 3(10):1215-20. PubMed ID: 15486188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase.
    Southgate TD; Garside E; Margison GP; Fairbairn LJ
    J Gene Med; 2006 Aug; 8(8):972-9. PubMed ID: 16733832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
    Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
    J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
    Bowman JE; Reese JS; Lingas KT; Gerson SL
    Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
    Cai S; Xu Y; Cooper RJ; Ferkowicz MJ; Hartwell JR; Pollok KE; Kelley MR
    Cancer Res; 2005 Apr; 65(8):3319-27. PubMed ID: 15833865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
    Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
    Jansen M; Sorg UR; Ragg S; Flasshove M; Seeber S; Williams DA; Moritz T
    Cancer Gene Ther; 2002 Sep; 9(9):737-46. PubMed ID: 12189523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.
    Sawai N; Zhou S; Vanin EF; Houghton P; Brent TP; Sorrentino BP
    Mol Ther; 2001 Jan; 3(1):78-87. PubMed ID: 11162314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear-localizing O6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection marker.
    Choi U; DeRavin SS; Yamashita K; Whiting-Theobald N; Linton GF; Loktionova NA; Pegg AE; Malech HL
    Exp Hematol; 2004 Aug; 32(8):709-19. PubMed ID: 15308322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
    Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
    Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
    Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
    Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.